2. Search Result
Search Result
Results for "

transgenic

" in MedChemExpress (MCE) Product Catalog:

74

Inhibitors & Agonists

5

Biochemical Assay Reagents

4

Peptides

2

Inhibitory Antibodies

11

Natural
Products

3

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-152857
    Muvalaplin

    LY3473329

    		 LDLR Cardiovascular Disease
    Muvalaplin (LY3473329) is an orally active, selective small molecule inhibitor of lipoprotein (a) (Lp (a)) that disrupts the initial non-covalent interaction between apo(a) and apoB100, preventing the disulphide bond and Lp(a) formation. Muvalaplin reduces the levels of Lp (a) in transgenic mice and in cynomolgus monkeys .
    Muvalaplin
  • HY-103157
    PD146176
    5 Publications Verification

    NSC168807

    		 Autophagy Ferroptosis Cardiovascular Disease
    PD146176 (NSC168807), a 15-Lipoxygenase (15-LO) inhibitor, inhibits rabbit reticulocyte 15-LO (Ki=197 nM, IC50=0.54 μM). PD146176 reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice .
    PD146176
  • HY-N1534
    Ponasterone A

    25-Deoxyecdysterone

    		 Others Others
    Ponasterone A (25-Deoxyecdysterone), an ecdysteroid, has strong affinity for the ecdysone receptor. Ponasterone A is a potent regulator of gene expression in cells and transgenic animals, enabling reporter genes to be turned on and off rapidly .
    Ponasterone A
  • HY-169421
    Nav1.7-IN-18

    		Sodium Channel Cancer
    Nav1.7-IN-18 (Compound 31) is a Nav1.7 inhibitor with a Ki value of 4.9 nM and an IC50 of 13 nM, showing analgesic effects in transgenic mice with inherited erythromelalgia (IEM) .
    Nav1.7-IN-18
  • HY-P4885
    Glp-amyloid-β (3-40) peptide (human)

    AβpE3-40

    		 Amyloid-β Neurological Disease
    Glp-Amyloid-β (3-40) Peptide (human) (AβpE3-40) is a minor amounts of pyroglutamate-modified Aβ isolated from from 24-month-old Amyloid precursor protein (APP) transgenic Mice .
    Glp-amyloid-β (3-40) peptide (human)
  • HY-103157R
    PD146176 (Standard)

    NSC168807 (Standard)

    		 Autophagy Ferroptosis Cardiovascular Disease
    PD146176 (Standard) is the analytical standard of PD146176. This product is intended for research and analytical applications. PD146176 (NSC168807), a 15-Lipoxygenase (15-LO) inhibitor, inhibits rabbit reticulocyte 15-LO (Ki=197 nM, IC50=0.54 μM). PD146176 reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice .
    PD146176 (Standard)
  • HY-50884
    BMS 433796

    		γ-secretase Neurological Disease
    BMS 433796 is a γ-secretase inhibitor with Aβ lowering activity in a transgenic mouse model of Alzheimer's disease.
    BMS 433796
  • HY-P1735
    Moth Cytochrome C (MCC) (88-103)

    		Cytochrome P450 Inflammation/Immunology
    Moth Cytochrome C (MCC) (88-103), derived from the carboxyl terminus of moth cytochrome c, induces positive selection of TCR transgenic thymocytes .
    Moth Cytochrome C (MCC) (88-103)
  • HY-163913
    SARS-CoV-IN-5

    		SARS-CoV Infection
    SARS-CoV-IN-5 (compound 49) is a highly selective, nonpeptidic and noncovalent 3CL pro inhibitor with IC50s of 38 nM, 21.1 nM and 86 nM for 3CL pro of SARS-CoV-1, SARS-CoV-2, Bat coronavirus WIV1, respectively. SARS-CoV-IN-5 inhibits the replication of the SARS-CoV-2 delta variant with an EC50 of 0.272 μM. SARS-CoV-IN-5 significantly reduces the lung viral copies in a K18-hACE2 transgenic mouse model. SARS-CoV-IN-5 has good target-specific and potential broad-spectrum anticoronavirus activities against SARS-CoV-1, WIV1, MERS, HCoV-OC43, HCoV-229E, and HKU9 .
    SARS-CoV-IN-5
  • HY-P1787
    β-Amyloid (4-10)

    		Amyloid-β Neurological Disease
    β-Amyloid (4-10) is an epitope for the polyclonal anti-Aβ(1-42) antibody, reduces amyloid deposition in a transgenic Alzheimer disease mouse model .
    β-Amyloid (4-10)
  • HY-147706
    AR524

    		Others Cancer
    Ar524 has higher inhibitory activity than the known transgenic inhibitor kifunensine. At the same time, ar524 inhibited low concentration (10 μ M) Spheroid formation of human malignant cells.
    AR524
  • HY-156842
    MCAAD-3

    		Amyloid-β Neurological Disease
    MCAAD-3 is a near-infrared Aβ imaging probe with blood-brain barrier penetrability. MCAAD-3 has a strong affinity for Aβ polymers (Ki >106 nM) and can label Aβ plaques in the brains of transgenic mice .
    MCAAD-3
  • HY-169224
    SARS-CoV-2-IN-100

    		SARS-CoV Infection
    SARS-CoV-2-IN-100 (Compound 172) is an inhibitor of SARS-CoV-2, demonstrating broad-spectrum antiviral activity against various SARS-CoV-2 variants. SARS-CoV-2-IN-100 exhibits synergistic effects with Nirmatrelvir, which can reduce the risk of antiviral drug resistance .
    SARS-CoV-2-IN-100
  • HY-B0957
    Erythromycin Ethylsuccinate

    Erythromycin ethyl succinate; EES

    		 Bacterial HIV Autophagy Antibiotic Infection
    Erythromycin Ethylsuccinate is an antibiotic useful for the treatment of a number of bacterial infections, has an antimicrobial spectrum similar to or slightly wider than that of penicillin. Erythromycin Ethylsuccinate has antiviral activity against HIV-1.
    Erythromycin Ethylsuccinate
  • HY-157261
    UNC2383

    		Others Others
    UNC2383 is an oligonucleotide enhancing compound that can enhance effects of antisense oligonucleotides (ASOs), and splice switching oligonucleotides (SSOs) .
    UNC2383
  • HY-149430
    YIAD-0205

    		Amyloid-β Neurological Disease
    YIAD-0205 is an orally available Aβ(1?42) aggregation inhibitor. YIAD-0205 demonstrated in vivo efficacy in an AD transgenic mouse model with five familial AD mutations (5XFAD) .
    YIAD-0205
  • HY-125172
    PolyQ aggregation inhibitor C2-8

    Polyglutamine Aggregation inhibitor III

    		 Huntingtin Others
    C2-8 is an inhibitor of polyglutamine (polyQ) aggregation (IC50s=25 and 0.05 μM for recombinant HDQ51 and in PC12 cells, respectively). It also inhibits polyQ aggregation in organotypic hippocampal slice cultures isolated from R6/2 transgenic mice and reduces neurodegeneration in a dose-dependent manner in a Drosophila model of Huntington's disease. C2-8 (100 and 200 mg/kg) reduces huntingtin aggregate size, reduces neuronal atrophy, and improves motor performance in a rotarod test in the R6/2 transgenic mouse model of Huntington's disease.
    PolyQ aggregation inhibitor C2-8
  • HY-124322
    NB-360

    		Beta-secretase Neurological Disease Inflammation/Immunology
    NB-360 is a potent, brain penetrable, and orally bioavailable dual BACE1/BACE2 inhibitor (IC50: mouse and human BACE1=5 nM; BACE2=6 nM). NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in amyloid precursor protein(APP) transgenic mice. NB-360 can completely block the progression of Aβ deposition in the brains of APP transgenic mice. NB-360 shows excellent selectivity over the related aspartyl proteases pepsin, cathepsin D and cathepsin E .
    NB-360
  • HY-164510
    N-Formyldemecolcine

    		Cytochrome P450 Others
    N-Formyldemecolcine is a colchicine precursor that contains the characteristic tropolone ring and pharmacophore of colchicine. N-Formyldemecolcine can be synthesized de novo by genetically engineering transgenic Nicotiana benthamiana and atypical cytochrome P450s that catalyze the production of colchicine's unique carbon scaffold .
    N-Formyldemecolcine
  • HY-N6608
    Physostigmine
    1 Publications Verification

    Eserine

    		 Cholinesterase (ChE) Neurological Disease
    Physostigmine (Eserine) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine can crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine is also an antidote for anticholinergic poisoning .
    Physostigmine
  • HY-101954
    Inarigivir

    ORI-9020; SB-9000

    		 HBV Infection
    Inarigivir (ORI-9020) is a dinucleotide antiviral drug that can significantly reduce liver HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir (ORI-9020) act as a RIG-I agonist to activate cellular innate immune responses .
    Inarigivir
  • HY-122989
    Aristolactam BIII

    		DYRK Inflammation/Immunology
    Aristolactam BIII is a potent DYRK1A inhibitor and inhibits the kinase activity of DYRK1A in vitro (IC50= 9.67 nM. Aristolactam BIII rescues the proliferative defects of DYRK1A transgenic (TG) mouse-derived fibroblasts and neurological and phenotypic defects of DS-like Drosophila models .
    Aristolactam BIII
  • HY-B0342A
    Meglumine (Excipient)

    Methylglucamine (Excipient); Meglumin (Excipient); Methylglucamin (Excipient)

    		 Biochemical Assay Reagents Cancer
    Meglumine (Methylglucamine) (Excipient) is an orally active amino sugar derived from sorbitol. Meglumine (Excipient) has anti-inflammatory and antitumor activity. Meglumine (Excipient) is often used as an excipient in active molecules and with iodinated compounds in contrast agents such as meglumine and meglumine iodide .
    Meglumine (Excipient)
  • HY-B0342
    Meglumine

    Methylglucamine; Meglumin; Methylglucamin

    		 Biochemical Assay Reagents Cancer
    Meglumine (Methylglucamine) is an orally active amino sugar derived from sorbitol. Meglumine has anti-inflammatory and antitumor activity. Meglumine is often used as an excipient in active molecules and with iodinated compounds in contrast agents such as meglumine and meglumine iodide .
    Meglumine
  • HY-B0342R
    Meglumine (Standard)

    		Biochemical Assay Reagents Cancer
    Meglumine (Standard) is the analytical standard of Meglumine. This product is intended for research and analytical applications. Meglumine (Methylglucamine) is an orally active amino sugar derived from sorbitol. Meglumine has anti-inflammatory and antitumor activity. Meglumine is often used as an excipient in active molecules and with iodinated compounds in contrast agents such as meglumine and meglumine iodide .
    Meglumine (Standard)
  • HY-172504
    DSPE-PEG5000-KAA

    		Liposome Cancer
    DSPE-PEG5000-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG5000-KAA can be used for drug delivery .
    DSPE-PEG5000-KAA
  • HY-172502
    DSPE-PEG1000-KAA

    		Liposome Cancer
    DSPE-PEG1000-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG1000-KAA can be used for drug delivery .
    DSPE-PEG1000-KAA
  • HY-172503
    DSPE-PEG2000-KAA

    		Liposome Cancer
    DSPE-PEG2000-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG2000-KAA can be used for drug delivery .
    DSPE-PEG2000-KAA
  • HY-B1266
    Physostigmine salicylate
    1 Publications Verification

    Eserine salicylate

    		 Cholinesterase (ChE) Neurological Disease
    Physostigmine salicylate (Eserine salicylate) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine salicylate crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine salicylate can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine salicylate is also an antidote for anticholinergic poisoning .
    Physostigmine salicylate
  • HY-N2320
    Physostigmine hemisulfate
    1 Publications Verification

    Eserine hemisulfate

    		 Cholinesterase (ChE) Neurological Disease
    Physostigmine hemisulfate (Eserine hemisulfate) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine hemisulfate can crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine hemisulfate can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine hemisulfate is also an antidote for anticholinergic poisoning .
    Physostigmine hemisulfate
  • HY-164547
    WHN-88

    		Porcupine Wnt β-catenin Cancer
    WHN-88 is a Porcupine (PORCN) inhibitor. WHN-88 can eliminate the palmitoylation of Wnt ligands, preventing their secretion and subsequent Wnt/β-catenin signaling. WHN-88 can inhibit cancer cell stemness and suppress the occurrence and development of breast tumors in MMTV-Wnt1 transgenic mice .
    WHN-88
  • HY-118543
    TM6089

    		HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease
    TM6089 is a unique Prolyl Hydroxylase (PHD) inhibitor which stimulates HIF activity without iron chelation and induces angiogenesis and exerts organ protection against ischemia. Local administration of TM6089 enhances angiogenesis, and oral administration stimulates HIF activity in transgenic rats expressing a hypoxia-responsive reporter vector .
    TM6089
  • HY-101954A
    Inarigivir ammonium

    ORI-9020 ammonium; SB-9000 ammonium

    		 HBV Infection Inflammation/Immunology
    Inarigivir (ORI-9020) ammonium is a dinucleotide antiviral drug that can significantly reduce liver HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir (ORI-9020) ammonium acts as a RIG-I (Retinoic acid-inducible gene-I) agonist to activate cellular innate immune responses .
    Inarigivir ammonium
  • HY-138669
    C004019

    		PROTACs Tau Protein Neurological Disease
    C004019 is a BBB-penatrable and small-molecule PROTAC that targets tau. C004019 can simultaneously recruit tau and E3 ligase, and effectively clear tau proteins by promoting the ubiquitination and proteasome-dependent degradation of tau, thereby improving synaptic and cognitive functions in Alzheimer's disease (AD) mice. C004019 can be used in the research of AD and tau protein-related diseases. (Pink: Ligand for target protein (HY-138679); Black: linker (HY-140189); Blue: E3 Ligase Ligand (HY-138678))
    C004019
  • HY-N6608S
    Physostigmine-d3

    Eserine-d3

    		 Isotope-Labeled Compounds Cholinesterase (ChE) Neurological Disease
    Physostigmine-d3 is the deuterium labeled Physostigmine. Physostigmine (Eserine) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine can crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine is also an antidote for anticholinergic poisoning[1][2][3][4].
    Physostigmine-d3
  • HY-139973
    OAB-14

    		Amyloid-β Neurological Disease
    OAB-14, is a Bexarotene (HY-14171) derivative, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice. OAB-14 effectively ameliorates the dysfunction of the endosomal-autophagic-lysosomal pathway in APP/PS1 transgenic mice .
    OAB-14
  • HY-16950
    4-Hydroxytamoxifen
    25+ Cited Publications

    (Z)-4-Hydroxytamoxifen; trans-4-Hydroxytamoxifen; (Z)-Afimoxifene

    		 Estrogen Receptor/ERR Cancer
    4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) is an orally active, selective estrogen receptor modulator (SERM). 4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) is also the active metabolic form of Tamoxifen (HY-13757A) in vivo and can be used to induce gene knockout in transgenic mice expressing CreER .
    4-Hydroxytamoxifen
  • HY-123033A
    Nicotinamide riboside chloride
    10+ Cited Publications

    		 Sirtuin Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    Nicotinamide riboside Chloride, an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside Chloride is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside Chloride reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .
    Nicotinamide riboside chloride
  • HY-123033
    Nicotinamide riboside

    		Sirtuin Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    Nicotinamide riboside, an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .
    Nicotinamide riboside
  • HY-N1414A
    3′,6-Disinapoylsucrose

    		Bcl-2 Family Apoptosis Neurological Disease
    3′,6-Disinapoylsucrose is a type of oligosaccharide that's effective when taken orally, and it has antidepressant, anti-anxiety, and antioxidant properties. 3′,6-Disinapoylsucrose inhibits neuronal apoptosis by lowering the ratio of Bax to Bcl-2 in hippocampal neurons, and it enhances cognitive function in APP/PS1 transgenic mice by activating the CREB/BDNF signaling pathway .
    3′,6-Disinapoylsucrose
  • HY-123033B
    Nicotinamide riboside tartrate

    		Sirtuin Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    Nicotinamide riboside tartrate, an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside tartrate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside tartrate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .
    Nicotinamide riboside tartrate
  • HY-123033C
    Nicotinamide riboside malate

    		Sirtuin Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    Nicotinamide riboside malate, an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside malate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside malate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .
    Nicotinamide riboside malate
  • HY-135470
    Nifurpirinol

    P-7138

    		 Antibiotic Bacterial Infection
    Nifurpirinol (P-7138) is a selective prosubstrate of bacterial nitroreductase (NTR). NTR catalyzes the reduction of nifurpirinol to generate cytotoxic metabolites that induce apoptosis in target cells. Nifurpirinol selectively ablates NTR-expressing cells such as pancreatic β cells, osteoblasts, dopaminergic neurons, and podocytes in transgenic zebrafish models. Nifurpirinol can be used in regeneration studies and disease modeling such as focal segmental glomerulosclerosis (FSGS) .
    Nifurpirinol
  • HY-123033D
    Nicotinamide riboside (triflate)

    		Endogenous Metabolite Sirtuin Neurological Disease Metabolic Disease Cancer
    Nicotinamide riboside (triflate), an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside (triflate) is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside (triflate) reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .
    Nicotinamide riboside (triflate)
  • HY-P99022
    Gantenerumab

    		Amyloid-β Neurological Disease
    Gantenerumab is a fully humanized anti-Aβ IgG1 monoclonal antibody. Gantenerumab can specifically bind to Aβ fibrils and plaques and can be used in Alzheimer's disease research .
    Gantenerumab
  • HY-12372
    Sanggenon G

    		IAP Caspase Cancer
    Sanggenon G is a cell-permeable and potent inhibitor of X-linked inhibitor of apoptosis protein (XIAP). Sanggenon G binds specifically to the BIR3 domain of XIAP with a binding affinity of 34.26 μM. Sanggenon G enhances caspase activation .
    Sanggenon G
  • HY-B1266R
    Physostigmine (salicylate) (Standard)

    		Cholinesterase (ChE) Neurological Disease
    Physostigmine (salicylate) (Standard) is the analytical standard of Physostigmine (salicylate). This product is intended for research and analytical applications. Physostigmine salicylate (Eserine salicylate) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine salicylate crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine salicylate can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine salicylate is also an antidote for anticholinergic poisoning .
    Physostigmine (salicylate) (Standard)
  • HY-100384
    NKL 22
    1 Publications Verification

    		 HDAC Neurological Disease
    NKL 22 (compound 4b) is a potent and selective inhibitor of histone deacetylases (HDAC), with an IC50 of 199 and 69 nM for HDAC1 and HDAC3, respectively. NKL 22 exhibits selectivity over HDAC2/4/5/7/8 (IC50≥1.59 μM). NKL 22 ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice .
    NKL 22
  • HY-145313
    TTBK1-IN-2

    		Tau Protein Neurological Disease
    TTBK1-IN-2 (compound 29) is a potent Tau-Tubulin kinase (TTBK1) inhibitor with IC50s of 0.24 and 4.22 µM, respectively. TTBK1-IN-2 reveals good brain penetration in vivo and is able to reduce TDP-43 phosphorylation not only in cell cultures but also in the spinal cord of transgenic TDP-43 mice .
    TTBK1-IN-2
  • HY-110002
    LFM-A13
    1 Publications Verification

    		 Polo-like Kinase (PLK) Btk JAK Cancer
    LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research
    LFM-A13